Adaptation of the Flag-Ida scheme in the National Cancer Institute: a valuable experience
Author Biography
Carmen Rosales, Clínica de Marly
Hematologa Clínica de Marly, Presidente de la Asociación Colombiana de Hematología y Oncología
References
Dieter Hoelzer, Nicola Gökbuget, Oliver Ottmann, Ching-Hon Pui, Mary V.F Relling, Frederick R. Appelbaum, Jacques J.M. van Dongen, Tomasz Szczepanski. Acute Lymphoblastic Leukemia. Hematology. 2001:162-8.
https://doi.org/10.1182/asheducation-2002.1.162
Jeffrey Szer. The prevalent predicament of relapsed acute myeloid leukemia. Hematology. 2012:43-8.
https://doi.org/10.1182/asheducation.V2012.1.43.3798183
Rowe JM, Goldstone AH. How I treat. Blood. 2007;110:2268-75.
https://doi.org/10.1182/blood-2007-05-038950
de la Rubia J, Regadera A, Martín G, Cervera J, Sanz G, Martínez J, Jarque I, García I, Andreu R, Moscardó F, Jiménez C, Mollá S, Benlloch L, Sanz M. FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patientswith high-risk myeloid malignancies. Leukemia Research. 2002;26:725-30.
https://doi.org/10.1016/S0145-2126(02)00003-6
Jackson GH. Use of fludarabine in the treatment of acute myeloid leukemia. The Hematology Journal. 2004;5 Suppl 1:S62-7.
https://doi.org/10.1038/sj.thj.6200392
Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, Ciuffreda L, Pietrantuono G, Liso V. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol. 2005;84:792-5.
https://doi.org/10.1007/s00277-005-1090-9
Milligan DW, Wheatley K, Littlewood T, Craig JI, Burnett AK, NCRI Haematological Oncology Clinical Studies Group. Burnett Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of randomized trial G-CSF and ATRA are not beneficial: results of the MRC AML-HR. Blood. 2006;107:4614-22.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
Article metrics | |
---|---|
Abstract views | |
Galley vies | |
PDF Views | |
HTML views | |
Other views |